Nationwide healthcare setting in Korea, including outpatient and inpatient care
Key Highlights
RTX use in vaccinated patients was associated with increased risk of COVID-19 hospitalization and ICU admission but not with increased SARS-CoV-2 infection risk.
No statistically significant association between RTX use and severe COVID-19 outcomes was found in unvaccinated patients.
Nationwide cohort data integrating COVID-19 registry and health insurance claims allowed robust adjustment for confounders including vaccination status and comorbidities.
Guideline-Based Recommendations
Diagnosis
Identify patients receiving anti-CD20 therapy such as rituximab who are at risk for severe COVID-19 outcomes.
Assess vaccination status and comorbidities to stratify risk.
Management
Carefully weigh risks and benefits of initiating or continuing rituximab therapy during the COVID-19 pandemic, especially in vaccinated individuals.
Consider enhanced monitoring and preventive measures for RTX-treated patients.
Monitoring & Follow-up
Monitor RTX-treated patients closely for signs of COVID-19 severity including hospitalization and ICU admission.
Track vaccination status and timing relative to RTX administration.
Risks
Increased risk of severe COVID-19 outcomes (hospitalization, ICU admission) in vaccinated patients receiving RTX.
Potential for prolonged viral shedding and severe pneumonia in RTX-treated patients.
Patient & Prescribing Data
1,548,038 adults requiring anti-CD20 therapy in Korea from 2020 to 2021, including 1,457,171 vaccinated and 90,867 unvaccinated individuals.
RTX initiation was linked to higher odds of severe COVID-19 outcomes in vaccinated patients but not significantly associated with infection risk or severe outcomes in unvaccinated patients.
Clinical Best Practices
Use propensity score matching and adjust for comorbidities and vaccination status when evaluating COVID-19 risk in RTX-treated patients.
Prioritize vaccination before RTX initiation when possible to mitigate severe COVID-19 risks.
Maintain vigilance for severe COVID-19 manifestations in RTX-treated patients despite vaccination.
